Patents by Inventor Ken J. Ishii

Ken J. Ishii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligodeoxynucleotide and its use to induce an immune response
    Patent number: 8741869
    Abstract: A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula: 5? N1N2N3T-CpG-WN4N5N6 3? wherein the CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are nucleotides, or the formula: 5? RY-CpG-RY 3? wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. In some embodiments, the oligodeoxynucleotide includes the nucleic acid sequences set forth as SEQ ID NO: 137.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: June 3, 2014
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Uniformed Services University of the Health Sciences, an institution of higher learning within the Department of Defense
    Inventors: Dennis M. Klinman, Ken J. Ishii, Daniela Verthelyi, James J. Mond
  • USE OF STERICALLY STABILIZED CATIONIC LIPOSOMES TO EFFICIENTLY DELIVER CPG OLIGONUCLEOTIDES IN VIVO
    Publication number: 20100104507
    Abstract: Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.
    Type: Application
    Filed: December 24, 2009
    Publication date: April 29, 2010
    Inventors: Dennis M. Klinman, Ihsan Gursel, Ken J. Ishii, Koji Kawakami, Bharat H. Joshi, Raj K. Puri
  • Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
    Patent number: 7666674
    Abstract: Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: February 23, 2010
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis M. Klinman, Ihsan Gursel, Ken J. Ishii